Does GLP-1 RA use improve survival and heart failure-related outcomes in adults with cancer therapy-related cardiac dysfunction on guideline-directed medical therapy?
In patients with cancer therapy-related cardiac dysfunction, GLP-1 receptor agonists may improve 1-year survival and heart failure outcomes.
BACKGROUND: Current anticancer treatments can result in cancer therapy-related cardiac dysfunction (CTRCD). While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated cardioprotective properties, their role in CTRCD has not been previously explored. METHODS: This retrospective cohort study utilized the TriNetX research network. Adults aged ≥18 years who had a cancer history and who underwent antineoplastic therapy and developed CTRCD between January 1, 2012 and January 1, 2023 were included. Among patients on guideline-directed medical therapy for heart failure, 2 groups were identified: GLP-1 RA users and nonusers. Propensity score matching (1:1) was conducted based on demographics, comorbid conditions, and concurrent medications, yielding a matched sample of 837 patients. Outcomes were assessed over a 1-year follow-up period. RESULTS: =0.009). While reductions in atrial fibrillation/flutter and ventricular tachycardia were observed, they were not statistically significant. CONCLUSION: Among patients with CTRCD receiving guideline-directed medical therapy, GLP-1 RA use may be linked to better 1-year survival and improved heart failure-related outcomes.
Vignarajah et al. (Thu,) studied this question.